Browse by Vaccine Type

This page shows data for Recombinant viral vector vaccine type.
Total Entries Retrieved: 53
IDVaccine NameDisease NameDisease ClassificationVirus NameNucleic Acid ContentVaccine TypeVaccine StatusManufacturerYear of ManufacturingManufacturing CountryAgeDosageAdministration RouteAdjuvantTarget StrainDescriptionApproving OrganisationCollaborating OrganisationOther CountriesTrade NamePMIDClinical Trial IDReference LinkAdditional Links
10013 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Approved AstraZeneca plc, University of Oxford, Serum Institute of India 2020 England NA 2 doses 28 days apart Intramuscular NA SARS-CoV-2 Spike gene to the replication defective chimpanzee adenovirus ChAdOx1 NA US FDA NA UK, USA, Japan, South Africa AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria 32328406 NA https://pubmed.ncbi.nlm.nih.gov/32328406/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637436/
10017 Convidecia COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Approved CanSino Biologics Inc. 2020 China 6 - 59 years 2 doses Intramuscular NA Spike protein of SARS-CoV-2 virus Viral vector vaccine using a replication-defective form of the human adenovirus Ad5 NMPA Jiangsu Province Centers for Disease Control and Prevention, Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China China, Chile, Hungary, Malaysia, Mexico, Pakistan Ad5-nCoV 32328406 NCT04916886 https://pubmed.ncbi.nlm.nih.gov/32328406/ https://extranet.who.int/pqweb/vaccines/convidecia
10018 JCOVDEN COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Approved Johnson & Johnson 2021 USA 18 - 65 years Single dose Intramuscular NA Spike protein of SARS-CoV-2 virus NA US FDA, WHO NA Netherlands, USA, Argentina, Brazil, Chile, Colombia, Mexico, Peru, Philippines, South Africa, Ukraine, Belgium, Colombia, France, Germany, Philippines, Spain, UK, Europe Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine 32328406 NCT04927936 https://pubmed.ncbi.nlm.nih.gov/32328406/ https://www.ema.europa.eu/en/documents/product-information/jcovden-previously-covid-19-vaccine-janssen-epar-product-information_en.pdf
10020 JCOVDEN COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Approved Janssen Pharmaceutical 2020 Russia NA 2 doses 21 days apart Intramuscular NA Heterologous formulation consisting of two human adenovirus vectors, Ad26 and Ad5, both carrying the SARS-CoV-2 spike protein NA US FDA Health Ministry of the Russian Federation NA Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine 32328406 NA https://pubmed.ncbi.nlm.nih.gov/32328406/ NA
10021 Gam-COVID-Vac COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Approved Gamaleya Research Institute of Epidemiology and Microbiology NA Russia NA 2 doses 3 weeks apart Intramuscular NA NA NA US FDA Health Ministry of the Russian Federation Russia, Bolivia, Argentina, Algeria, Serbia, Belarus Sputnik-V NA NA https://www.precisionvaccinations.com/vaccines/sputnik-v-vaccine NA
10022 Gam-COVID-Vac COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Approved Gamaleya Research Institute of Epidemiology and Microbiology NA Russia NA NA Intramuscular NA NA NA EMA NA NA Sputnik-V 33324769 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729279/ NA
10044 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Approved AstraZeneca plc, University of Oxford, Serum Institute of India 2020 UK NA NA Intramuscular NA NA Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2 EMA NA NA AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria NA NA https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf NA
10045 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Approved AstraZeneca plc, University of Oxford, Serum Institute of India NA India NA NA Intramuscular NA NA Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2 DCGI NA NA AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria NA NA https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf NA
10050 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Approved AstraZeneca plc, University of Oxford, Serum Institute of India NA UK NA NA Intramuscular NA NA Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2 Japan MHLW NA NA AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria NA NA https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf https://www.who.int/publications/m/item/chadox1-s-recombinant-covid-19-vaccine
10051 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Approved AstraZeneca plc, University of Oxford, Serum Institute of India NA UK NA NA Intramuscular NA NA Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2 Australia TGA NA NA AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria NA NA https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf https://www.who.int/publications/m/item/chadox1-s-recombinant-covid-19-vaccine
10085 Ad26.ZEBOV Ebola Hemorrhagic Zaire ebolavirus negative-sense, single-stranded RNA Recombinant viral vector Approved Janssen Pharmaceutical 2020 USA 1 year and above Single dose of Zabdeno on day 0 followed by 0.5mL dose of Mvabea post 8 week Intramuscular NA Adenovirus type 26 encoding the Zaire ebolavirus, Mayinga variant glycoprotein NA US FDA, EMA NA NA MVA-BN-Filo NA NCT02509494 https://clinicaltrials.gov/ct2/show/NCT02509494 https://clinicaltrials.gov/ct2/show/NCT05284097
10108 Hecolin (Hepatitis vaccine -239) Hepatitis E Hepatitic Hepatitis E virus double stranded DNA Recombinant viral vector Approved Xiamen Innovax Biotech 2011 China NA 3 doses at regimen of 0, 1, and 6 months Intramuscular Aluminum (aluminium hydroxide) Capsid Protein ORF2 NA China FDA NA NA Hecolin 29546064 NCT01014845 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818934/ https://www.precisionvaccinations.com/vaccines/hecolin-hepatitis-e-vaccine
10148 MVA-SARS-2-S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Universitätsklinikum Hamburg-Eppendorf 2021 Germany 18 - 55 years 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA Ludwig-Maximilians, University of Munich NA NA NA NCT04569383 https://clinicaltrials.gov/show/NCT04569383 NA
10156 VXA-CoV2-1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Vaxart 2021 USA 18 - 55 years 2 doses 28 days apart Oral NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA 33937326 NCT04563702 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10157 VXA-CoV2-1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Vaxart 2021 USA 18 - 54 years 2 doses 28 days apart Oral NA NA Ad5 adjuvanted Oral Vaccine platform NA NA NA NA 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10160 CVXGA1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 CyanVac LLC 2021 USA 18 - 75 years Single dose Intranasal NA Spike protein of SARS-CoV-2 virus NA US FDA NA NA PIV5-SARS CoV-2 vaccine NA NCT04954287 https://clinicaltrials.gov/ct2/show/NCT04954287 NA
10161 COVID-19 rNDV vector vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Laboratorio Avi-Mex 2021 Mexico 18 - 55 years 2 doses 21 days apart Intramuscular NA NA NA NA NA NA NA NA NCT04871737 https://clinicaltrials.gov/ct2/show/study/NCT04871737 NA
10179 ChAdV68-S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Gritstone Oncology 2021 USA 18 years and above 2 doses 28 days apart Intramuscular Aluminum (alum) SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA NA NCT04760743 https://clinicaltrials.gov/ct2/show/NCT04760743 NA
10184 SC-Ad6-1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Tetherex Pharmaceuticals Corporation 2021 Australia 18 - 55 years Single or multiple-dose Intramuscular, Intranasal NA NA NA NA NA NA NA NA NCT04839042 https://clinicaltrials.gov/ct2/show/NCT04839042 NA
10196 MVA-MERS-S MERS Respiratory MERS-CoV positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Philipps University Marburg Medical Center 2020 Germany 18 - 55 years 2 doses 28 days apart Intramuscular NA MERS CoV spike glycoprotein NA NA NA NA NA 32325037 NCT03615911 https://pubmed.ncbi.nlm.nih.gov/32325037/ NA
10197 MVA-MERS-S_DF1 MERS Respiratory MERS-CoV positive-sense, single-stranded RNA Recombinant viral vector Phase 1 CTC North GmbH & Co. KG 2021 Germany 18 - 55 years NA Intramuscular NA MERS CoV spike glycoprotein NA NA NA NA NA 33341119 NCT04119440 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7749790/ NA
10202 rVSV-EBOV Ebola Hemorrhagic Zaire ebolavirus negative-sense, single-stranded RNA Recombinant viral vector Phase 1 Merck & Co. Inc. 2014 USA 18 - 65 years NA Intramuscular NA Zaire Ebola virus glycoprotein Vesicular Stomatitis Virus based NA National Institute of Allergy and Infectious Diseases NA NA 27764560 NCT02280408 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/ NA
10203 Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO)/ChAd3-EBO-Z Ebola Hemorrhagic Zaire ebolavirus negative-sense, single-stranded RNA Recombinant viral vector Phase 1 National Institute of Allergy and Infectious Diseases 2014 USA 18 - 65 years NA Intramuscular NA Wild type glycoproteins from Zaire and Sudan strains of Ebolavirus Chimpanzee Adenovirus Vector expressing Zaire and sudan strain glycoprotein NA NA NA NA 27764560 NCT02231866 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/ NA
10208 cAd3 Marburg (VRC-MARADC087-00-VP) Marburg hemorrhagic fever Hemorrhagic Marburg virus negative-sense, single-stranded RNA Recombinant viral vector Phase 1 National Institute of Allergy and Infectious Diseases 2021 USA 18 - 50 years Single dose Intramuscular NA Marburg wild type glycoprotein NA US FDA US Military HIV Research Program NA NA NA NCT03475056 https://clinicaltrials.gov/ct2/show/NCT03475056?cond=Marburg+hemorrhagic+fever&draw=2&rank=3 NA
10228 CHIK001 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 University of Oxford 2019 NA 18 - 50 years NA NA NA Chimpanzee adenovirus expressing CHIKV structural proteins NA NA NA NA NA NA NCT03590392 https://link.springer.com/chapter/10.1007/82_2019_175 https://clinicaltrials.gov/ct2/show/NCT03590392?cond=Chickungunya+Fever&draw=2&rank=29
10231 VLA1533 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Recombinant viral vector Phase 1 Valneva 2019 Austria 18 - 39 years 3 doses on day 0, 28 and 56 Intramuscular NA NA NA NA NA NA NA NA NCT03010228 https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006919 https://clinicaltrials.gov/ct2/show/NCT03010228
10250 COVID-19 Vaccine Nasal Spray COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 Xiamen University 2021 China 18 years and above 2 doses 14 days apart Intranasal NA NA NA NA University of Hong Kong, Beijing Wantai Biological Pharmacy NA NA 33937326 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10251 hAd5-COVID-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 ImmunityBio Inc. 2021 USA 18 - 80 years NA Subcutaneous NA Spike & Nucleocapsid protein NA NA NA NA NA 33937326 NCT04843722 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10260 AV-COVID-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 Aivita Biomedical Inc. 2021 USA 18 years and above Single dose Intramuscular GM-CSF Spike protein of SARS-CoV-2 virus NA US FDA NA NA NA 33816047 NCT05007496 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://clinicaltrials.gov/ct2/show/NCT05007496
10261 MVA-SARS-2-S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 City of Hope Medical Center, National Cancer Institute 2021 USA 18 years and above 2 doses 28 days apart Intramuscular NA Spike protein of SARS-CoV-2 virus NA US FDA NA NA COH04S1 33816047 NCT04977024 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10262 hAd5-COVID-19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 ImmunityBio Inc. 2021 USA 18 - 80 years Single dose Subcutaneous NA Spike & nucleocapsid protein of SARS-CoV-2 virus NA US FDA NA NA NA 33816047 NCT04843722 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10279 COVIVAC COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 Icahn School of Medicine, Mahidol University 2021 Thailand 18 - 75 years 2 doses 28 days apart Intramuscular CpG 1018 Spike protein of SARS-CoV-2 virus NA NA NA NA ADAPTCOV, NDV-HXP-S vaccine, , HXP-GPOVac, Patria, ButanVac NA NCT04764422 https://clinicaltrials.gov/show/NCT04764422 NA
10284 MVA-SARS-2-ST COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 German Center for Infection Research 2021 Germany 18 years and above 2 doses 28 days apart Intramuscular NA Modified Vaccinia Virus Ankara vector expressing a stabilized SARS-CoV-2 spike protein NA NA NA NA NA NA NCT04895449 https://clinicaltrials.gov/ct2/show/NCT04895449 NA
10290 AAV5-RBD-S COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 Biocad 2021 Russia 18 - 60 years NA Intramuscular NA SARS-CoV-2 receptor-binding domain from spike protein NA NA NA NA NA NA NCT05037188 https://clinicaltrials.gov/ct2/show/NCT05037188 NA
10291 AdCLD-CoV19 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 Cellid Co. Ltd. 2021 South Korea 19 - 64 years Single dose Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA NA NA NA NA NCT04666012 https://clinicaltrials.gov/ct2/show/NCT04666012 NA
10294 cAd3-EBO Ebola Hemorrhagic Zaire ebolavirus negative-sense, single-stranded RNA Recombinant viral vector Phase 2 Centre Hospitalier Universitaire Vaudois 2014 Switzerland 18 - 65 years NA Intramuscular NA Zaire Ebola virus glycoprotein Chimpanzee Adenovirus Vector expressing Zaire strain glycoprotein NA NA NA NA 27764560 NCT02289027 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287303/ NA
10296 rHEV Hepatitis E Hepatitic Hepatitis E virus double stranded DNA Recombinant viral vector Phase 2 GlaxoSmithKline 2011 USA 18 - 58 years 3 doses at regimen of 0, 1, and 6 months NA Aluminum (alum) Capsid Protein ORF2 NA NA National Institute of Health, Novavax NA NA NA NA https://www.who.int/immunization/sage/meetings/2014/october/4_Hepatitis_E_vaccine_pipeline_final_29_Sept_14.pdf NA
10305 MV/Schwarz Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Recombinant viral vector Phase 2 NA NA NA NA NA NA NA CHIKV structural proteins NA NA NA NA NA NA NA https://link.springer.com/chapter/10.1007/82_2019_175 NA
10308 MVA-mBN85B Measles Exanthous Morbillivirus negative-sense, single-stranded RNA Recombinant viral vector Phase 2 Bavarian Nordic 2012 South Africa 6 months - 6 years 2 doses 4 weeks apart Subcutaneous NA Attenuated Modified Vaccinia Virus Ankara, strain encoding hemagglutinin protein, fusion protein and nucleoprotein of measles virus NA NA NA NA Rouvax NA NCT00891007 https://clinicaltrials.gov/ct2/show/NCT00891007?recrs=abde&cond=measles+vaccines&phase=123&draw=2&rank=3 NA
10322 Convidecia COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 3 CanSino Biologics Inc. NA China NA Single dose Intramuscular NA NA NA NA Beijing Institute of Biotechnology NA Adenovirus type 5 vector 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10328 BriLife COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 3 Israel Institute for Biological Research 2021 Israel 18 - 55 years NA Intramuscular NA Spike protein of SARS-CoV-2 virus NA NA Weizmann Institute of Science NA IIBR-100 33937326 NCT04990466 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082173/ NA
10329 GRAd-COV2 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 3 ReiThera Srl 2021 Italy 18 years and above 2 doses 21 days apart Intramuscular Replication defective Simian Adenovirus (GRAd) encoding S Spike protein of SARS-CoV-2 virus NA NA NA NA NA 33816047 NCT04791423 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10336 Covishield COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Recombinant viral vector Phase 3 AstraZeneca plc 2021 Brazil 18 years and above 2 doses 28 days apart Intramuscular NA SARS-CoV-2 variant strain B.1.351 NA NA NA Brazil, UK, South Africa AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria NA NCT04973449 https://clinicaltrials.gov/ct2/show/NCT04973449 NA
10361 Ad26. RSV. preF Respiratory syncytial virus infection Respiratory Respiratory syncytial virus negative-sense, single-stranded RNA Recombinant viral vector Phase 3 Janssen Pharmaceutical 2021 USA 18 - 59 years 2 doses 6 months apart Intramuscular NA Fusion glycoprotein of RSV NA US FDA NA NA NA NA NCT05070546 https://clinicaltrials.gov/ct2/show/NCT05070546?recrs=bde&cond=Respiratory+Syncytial+Virus+%28RSV%29&phase=23&draw=2&rank=8 https://www.fda.gov/media/105619/download
10394 CAdVax-CHIK Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Recombinant viral vector Preclinical GenPhar Inc. NA NA NA Single dose NA NA CHIKV structural proteins Produced in HEK293 packaging cell line NA NA NA NA NA NA https://academic.oup.com/jid/article/214/suppl_5/S488/2632628 https://www.sciencedirect.com/science/article/pii/S0264410X16300731
10395 MVA-CHIKV Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Recombinant viral vector Preclinical NA NA NA NA Single dose NA NA CHIKV structural proteins NA NA NA NA NA NA NA https://academic.oup.com/jid/article/214/suppl_5/S488/2632628 NA
10402 VSVdelG-CHIKV Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Recombinant viral vector Preclinical NA NA NA NA NA NA NA Glycoprotein-deficient VSV encoding CHIKV structural proteins NA NA NA NA NA NA NA https://link.springer.com/chapter/10.1007/82_2019_175 NA
10403 VEE/CHIKV Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Recombinant viral vector Preclinical NA NA NA NA NA NA NA Chimera consisting of VEEV nsP and CHIKV structural proteins NA NA NA NA VEE/IRES-C/CHIKV NA NA https://link.springer.com/chapter/10.1007/82_2019_175 NA
10404 EILV/CHIKV Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Recombinant viral vector Preclinical NA NA NA NA NA NA NA Eilat virus nonstructural and CHIKV structural proteins NA NA NA NA NA NA NA https://link.springer.com/chapter/10.1007/82_2019_175 NA
10405 CAdVax-CHIK Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Recombinant viral vector Preclinical NA NA NA NA NA NA NA Replication-deficient Ad5 encoding CHIKV structural proteins NA NA NA NA NA NA NA https://link.springer.com/chapter/10.1007/82_2019_175 NA
10406 MVA-6KE1E3E2 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Recombinant viral vector Preclinical NA NA NA NA NA NA NA MVA encoding CHIKV structural proteins NA NA NA NA NA NA NA https://link.springer.com/chapter/10.1007/82_2019_175 NA
10407 MVA-E2E3 Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Recombinant viral vector Preclinical NA NA NA NA NA NA NA CHIKV envelope protein (E2, E3) NA NA NA NA NA NA NA https://link.springer.com/chapter/10.1007/82_2019_175 NA
10408 MVA-CHIKV Chikungunya fever Exanthous Chikungunya virus positive-sense, single-stranded RNA Recombinant viral vector Preclinical NA NA NA NA NA Intraperitoneal NA CHIKV structural proteins (C, E3, E2, 6K, E1) into MVA NA NA NA NA NA NA NA https://link.springer.com/chapter/10.1007/82_2019_175 NA